News | October 26, 2021
ANG Life Sciences India H1FY22 consolidated PAT zooms to Rs. 33.77 crore
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastbone, da Vinci Xi's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control
InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Nureca Ltd has reported financial results for the period ended June 30, 2021.
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Subscribe To Our Newsletter & Stay Updated
